Tscan therapeutics reports second quarter 2023 financial results and provides corporate update

Presented preliminary phase 1 clinical data from heme malignancies trial at the asgct 26th annual meeting; expect to reach recommended phase 2 dose for two tcr-t therapy product candidates and report interim data by year-end 2023
TCRX Ratings Summary
TCRX Quant Ranking